- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05911243
Faisabilité de l'acupression auriculaire pour l'appétit et le poids chez les patients atteints d'un cancer de l'estomac, de l'œsophage et du pancréas de stade II à IV
Un essai contrôlé randomisé testant les effets d'une intervention d'acupression sur l'appétit et le poids chez des patients atteints d'un cancer de l'estomac, de l'œsophage et du pancréas : une étude pilote et de faisabilité
This clinical trial evaluates the feasibility and acceptability of acupressure to the ear (auricular) to address appetite and weight in patients with stage II-IV gastric, esophageal, or pancreatic cancer. Cancer anorexia, the abnormal loss of appetite, directly leads to cancer-associated weight loss (cachexia) through malnourishment, reduced caloric intake, treatment side-effects, and other modifiable risk factors. Cachexia prolongs length of hospital stay for patients, negatively impacts treatment tolerance and adherence, and reduces overall patient quality of life. Auricular acupressure is a form of micro-acupuncture that exerts its effect by stimulating the central nervous system using adhesive taped pellets applied to specific locations on the external ear. The use of these pellets to deliver auricular acupressure has been shown to improve pain, fatigue, insomnia, nausea and vomiting, depression, and quality of life in both cancer and non-cancer settings. Auricular acupressure is a safe, inexpensive, and non-invasive approach to addressing cancer-related symptoms and treatment side-effects and may be effective at improving appetite and weight loss in stage II-IV gastric, esophageal, and pancreatic cancer patients.
Aperçu de l'étude
Statut
Les conditions
- Cancer du pancréas de stade II AJCC v8
- Cancer du pancréas de stade III AJCC v8
- Cancer du pancréas de stade IV AJCC v8
- Cancer gastrique de stade clinique III AJCC v8
- Cancer gastrique de stade IV clinique AJCC v8
- Adénocarcinome de l'œsophage de stade clinique II AJCC v8
- Carcinome épidermoïde de l'œsophage de stade clinique II AJCC v8
- Cancer gastrique de stade clinique II AJCC v8
- Adénocarcinome de l'œsophage de stade clinique III AJCC v8
- Carcinome épidermoïde de l'œsophage de stade clinique III AJCC v8
- Adénocarcinome de l'œsophage de stade clinique IV AJCC v8
- Carcinome épidermoïde de l'œsophage de stade clinique IV AJCC v8
Description détaillée
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.
ARM II: Patients receive usual care on study. Patients also undergo collection of blood samples on study.
After completion of study treatment, patients in Arm II are followed up at 8 weeks after active treatment ends.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 18-65 years of age
- Stage II-IV gastric, esophageal, or pancreatic cancer
- Appetite score on visual analog scale ≤ 70/100
- At least 60 days of planned systemic treatment, whether already initiated or scheduled to be initiated
- Access to phone and electronic device for study contacts and questionnaires
- Willing and able to attend 4 in-person auricular acupressure treatments at the Fred Hutch South Lake Union Clinic
- Willing and able to perform 4 at-home self-applied treatments of auricular acupressure
- Participants must not have received acupressure or acupuncture for low appetite within last 30 days
- Participants must not be actively using corticosteroids, mirtazapine (Remeron), olanzapine (Zyprexa), or Marinol for appetite stimulation at baseline
- Participants must be able to intake food orally and not require sole or supplemental intravenous nutrition at baseline
- Participants must not have a history of physiological eating disorders (e.g., anorexia nervosa) in the last 3 years
- Participants must not have a current known or diagnosed immunodeficiency
- Participants must have an intact auricular pinna
- Able to understand and willing to sign written informed consent in English
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm I (acupressure therapy)
Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study. |
Ancillary studies
Autres noms:
Undergo collection of blood samples
Autres noms:
Receive usual care
Autres noms:
Undergo auricular acupressure
Autres noms:
|
|
Comparateur actif: Arm II (usual care)
Patients receive usual care on study. Patients also undergo collection of blood samples on study. |
Ancillary studies
Autres noms:
Undergo collection of blood samples
Autres noms:
Receive usual care
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Accrual (Feasibility)
Délai: Up to 2 years, during study accrual
|
Accrual will be measured by the average rate of participants-per-month enrolled into both groups with the goal of 5 patients/month over a 15-month period. |
Up to 2 years, during study accrual
|
|
Retention (Feasibility)
Délai: Up to 8 weeks
|
Retention will be measured by the number of participants who remain in the trial and provide data at the closeout visit. |
Up to 8 weeks
|
|
Intervention Adherence (Feasibility)
Délai: Up to 8 weeks
|
Adherence will be measured in the intervention group by the number of applied auricular acupressure treatments, with the total possible being 8. |
Up to 8 weeks
|
|
Intervention Fidelity (Feasibility)
Délai: Up to 8 weeks
|
Fidelity will be assessed by study team adherence to symptom query and appropriate ear seed point modifications to the standard protocol and accuracy of seed placement according to photographic analysis. |
Up to 8 weeks
|
|
Acceptability (Feasibility)
Délai: Up to 16 weeks
|
Acceptability will be assessed using a random convenience sample of participants and providers through semi-structured interviews. |
Up to 16 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Appetite
Délai: Baseline to week 4
|
As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 4. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response. |
Baseline to week 4
|
|
Change in Appetite
Délai: Baseline to week 8
|
As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 8. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response. |
Baseline to week 8
|
|
Change in Body Weight (kg)
Délai: Baseline to week 4
|
Analyses will assess change in each outcome as a change from baseline to week 4. |
Baseline to week 4
|
|
Change in Body Weight (kg)
Délai: Baseline to week 8
|
Analyses will assess change in each outcome as a change from baseline to week 8. |
Baseline to week 8
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Blake Langley, Fred Hutch/University of Washington Cancer Consortium
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Tumeurs par site
- Tumeurs
- Tumeurs du système digestif
- Maladies du système digestif
- Tumeurs des glandes endocrines
- Maladies pancréatiques
- Tumeurs pancréatiques
- Administration des services de santé
- Qualité des soins de santé, accès et évaluation
- Techniques d'investigation
- Thérapeutique
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Qualité des soins de santé
- Thérapies complémentaires
- Modalités de physiothérapie
- Indicateurs de qualité, soins de santé
- Réhabilitation
- Lignes directrices comme sujet
- Assurance qualité, soins de santé
- Thérapie, tissus mous
- Manipulations musculo-squelettiques
- Standard de soins
- Manipulation des échantillons
- Pratiquez les directives comme sujet
- Acupression
Autres numéros d'identification d'étude
- RG1123492
- RG1123492 (Autre identifiant: Fred Hutch/University of Washington Cancer Consortium)
- NCI-2023-03942 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- 3KL2TR002317 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data that underlie the results reported in published articles after de-identification may be made available upon request (text, tables, figures, and appendices).
Délai de partage IPD
Beginning 6 months and ending 36 months after publication of results or study protocol, as requested.
Critères d'accès au partage IPD
Researchers and investigators who: 1) provide a methodologically sound proposal to expand on aims in the original, approved proposal; and/or 2) aim to conduct individual, participant-level meta-analyses. Proposals should be directed to blangley@fredhutch.org. To gain access, data requestors will need to sign a data access agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .